ACXP

Acurx Pharmaceuticals, Inc.

Price Chart

Latest Quote

$1.68

-0.09 (-5.08%)

Current Price

Previous Close	$1.77
Open	$1.77
Day High	$1.77
Day Low	$1.62
Volume	96,851

Fetched: 2026-06-06T02:22:52

Stock Information

Shares Outstanding	4.30M
Cash Equivalents	$9.25M
Net Income	$-7.50M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.22M
EPS (TTM)	$-3.79
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-2.03M
Income	$-7.50M
Book/sh	$2.07
Cash/sh	$2.15
Employees	4

Financial Ratios

Quick Ratio	3.69
Current Ratio	3.77

Returns & Margins

ROA	-66.50%
ROE	-160.83%

Ownership

Insider Ownership	2.99%
Institutional Ownership	6.20%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.79
P/B	0.81

Analyst Data

Recommendation	none
Target Price	$17.00

Technical Indicators

SMA20	$1.92
SMA50	$2.38
SMA200	$3.55
RSI	33.33
ATR	0.1442

Shares Float	4.15M
Short Float	3.44%
Short Ratio	0.94
Rel Volume	0.88

Performance History

Week	-15.15%
Month	-19.62%
Quarter	+24.44%
6 Months	-48.78%
YTD	-39.13%
Year	-76.34%
3 Years	-97.29%
10 Years	-98.94%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$1.68	96,851
2026-06-04	$1.77	35,500
2026-06-03	$1.75	115,700
2026-06-02	$1.80	147,200
2026-06-01	$1.93	101,200
2026-05-29	$1.98	62,100
2026-05-28	$1.99	72,700
2026-05-27	$1.99	87,800
2026-05-26	$1.94	125,700
2026-05-22	$1.97	249,400
2026-05-21	$1.93	70,200
2026-05-20	$1.89	46,200
2026-05-19	$1.88	155,500
2026-05-18	$1.80	96,000
2026-05-15	$1.92	112,400
2026-05-14	$1.94	96,300
2026-05-13	$1.99	106,700
2026-05-12	$2.05	250,900
2026-05-11	$2.18	109,100
2026-05-08	$2.09	60,000
2026-05-07	$2.12	76,100
2026-05-06	$2.09	70,300

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

📰 Latest News

Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-12T17:05:41Z

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Zacks • 2026-04-02T13:40:03Z

Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...

GuruFocus.com • 2026-03-24T01:00:31Z

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

Zacks • 2026-03-19T13:55:02Z

Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?

Zacks • 2026-03-17T13:40:04Z

BC-Most Active Stocks

Associated Press Finance • 2026-03-11T14:30:34Z

Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Insider Monkey • 2026-02-24T18:12:07Z

Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term

Simply Wall St. • 2026-01-21T12:28:16Z

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Zacks • 2026-01-06T14:40:03Z

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

Zacks • 2025-06-18T13:40:03Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$8,091,983	$14,123,227	$14,577,768	$12,092,776
Net Non Operating Interest Income Expense	$125,445	$20,124	-	-
Operating Expense	$8,091,983	$14,123,227	$14,577,768	$12,092,776
General And Administrative Expense	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Other Income Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Interest Income	$125,445	$20,124	-	-
Interest Income	$125,445	$20,124	-	-
Normalized Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income From Continuing And Discontinued Operation	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Common Stockholders	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Including Noncontrolling Interests	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Net Income Continuous Operations	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Pretax Income	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Interest Income Non Operating	$125,445	$20,124	-	-
Operating Income	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-5.32	$-17.45	$-23.00	$-22.40
Basic EPS	$-5.32	$-17.45	$-23.00	$-22.40
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
EBITDA (Bullshit earnings)	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
EBIT	$-8,091,983	$-14,123,227	$-14,577,768	$-12,092,776
Diluted Average Shares	$1,498,793	$808,168	$633,578	$540,820
Basic Average Shares	$1,498,793	$808,168	$633,578	$540,820
Diluted NI Availto Com Stockholders	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Research And Development	$1,834,506	$5,403,836	$6,043,597	$4,754,271
Selling General And Administration	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Other Gand A	$6,257,477	$8,719,391	$8,534,171	$7,338,505
Total Unusual Items	-	-	-	$0
Total Unusual Items Excluding Goodwill	-	-	-	$0
Other Special Charges	-	-	-	-

Fetched: 2026-05-30

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Assets	$7,689,535	$3,857,963	$7,709,123	$9,376,706
Total Non Current Assets	$0	$0	$0	$0
Current Assets	$7,689,535	$3,857,963	$7,709,123	$9,376,706
Prepaid Assets	$85,018	$100,123	$105,776	$264,955
Receivables	$48,417	$51,127	$129,159	$0
Other Receivables	$48,417	$51,127	$129,159	-
Cash Cash Equivalents And Short Term Investments	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Cash And Cash Equivalents	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Cash Financial	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Liabilities
Total Liabilities Net Minority Interest	$2,420,943	$3,242,842	$3,042,438	$2,061,685
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$0
Current Liabilities	$2,420,943	$3,242,842	$3,042,438	$2,061,685
Payables And Accrued Expenses	$2,381,932	$2,705,212	$2,326,131	$1,518,790
Payables	$6,802	$4,787	$3,809	$29,539
Other Payable	$6,802	$4,787	$3,809	$29,539
Equity
Common Stock Equity	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Equity Gross Minority Interest	$5,268,592	$615,121	$4,666,685	$7,315,021
Stockholders Equity	$5,268,592	$615,121	$4,666,685	$7,315,021
Retained Earnings	$-75,288,494	$-67,321,956	$-53,218,853	$-38,641,085
Gains Losses Not Affecting Retained Earnings	-	-	-	$-38,641,085
Other Equity Adjustments	-	-	-	$-38,641,085
Other
Ordinary Shares Number	$2,348,113	$851,534	$723,411	$581,380
Share Issued	$2,348,113	$851,534	$723,411	$581,380
Tangible Book Value	$5,268,592	$615,121	$4,666,685	$7,315,021
Invested Capital	$5,268,592	$615,121	$4,666,685	$7,315,021
Working Capital	$5,268,592	$615,121	$4,666,685	$7,315,021
Total Capitalization	$5,268,592	$615,121	$4,666,685	$7,315,021
Additional Paid In Capital	$80,554,738	$67,936,225	$57,871,070	$45,944,478
Capital Stock	$2,348	$852	$14,468	$11,628
Common Stock	$2,348	$852	$14,468	$11,628
Pensionand Other Post Retirement Benefit Plans Current	$39,011	$537,630	$716,307	$542,895
Current Accrued Expenses	$2,375,130	$2,700,425	$2,322,322	$1,489,251
Treasury Shares Number	-	-	$0	-
Total Partnership Capital	-	-	$-53,218,853	$-38,641,085

Fetched: 2026-05-30

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Operating Activities
Operating Cash Flow	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Cash Flow From Continuing Operating Activities	$-6,787,782	$-10,383,431	$-9,800,885	$-7,542,290
Operating Gains Losses	-	-	-	-
Financing Activities
Repurchase Of Capital Stock	$-1,040	$0	-	-
Issuance Of Capital Stock	$6,797,112	$6,405,757	$5,944,250	$3,695,182
Financing Cash Flow	$10,637,169	$6,615,956	$8,163,322	$3,695,195
Cash Flow From Continuing Financing Activities	$10,637,169	$6,615,956	$8,163,322	$3,695,195
Net Common Stock Issuance	$6,796,072	$6,405,757	$5,944,250	$3,695,182
Common Stock Issuance	$6,797,112	$6,405,757	$5,944,250	$3,695,182
Other
End Cash Position	$7,556,100	$3,706,713	$7,474,188	$9,111,751
Beginning Cash Position	$3,706,713	$7,474,188	$9,111,751	$12,958,846
Changes In Cash	$3,849,387	$-3,767,475	$-1,637,563	$-3,847,095
Proceeds From Stock Option Exercised	$3,841,097	$210,199	$2,219,072	$13
Common Stock Payments	$-1,040	$0	-	-
Change In Working Capital	$-390,964	$284,089	$1,010,773	$1,248,125
Change In Payables And Accrued Expense	$-408,779	$200,404	$980,753	$1,217,776
Change In Prepaid Assets	$15,105	$5,653	$159,179	$30,349
Change In Receivables	$2,710	$78,032	$-129,159	$0
Stock Based Compensation	$1,569,720	$3,435,583	$3,766,110	$3,302,361
Net Income From Continuing Operations	$-7,966,538	$-14,103,103	$-14,577,768	$-12,092,776
Other Non Cash Items	-	-	$559,583	$430,680
Pension And Employee Benefit Expense	-	-	-	$0
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Issuance	-	-	-	-

Fetched: 2026-05-30